Gregory S. Felzien, MD, AAHIVS; Andrea R. Jefferson-Saboor, FNP-C
This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Gregory S. Felzien, MD, AAHIVS
Division of Health Protection/IDI-HIV
Georgia Department of Public Health
Andrea R. Jefferson-Saboor, FNP-C
Family Nurse Practitioner
Faebris Medical and Community Education
Preexposure prophylaxis (PrEP) is a broad set of clinical tools that can be used to reduce the chances of acquiring human immunodeficiency virus (HIV). Although it is highly effective, many people who could benefit from PrEP lack access or are not familiar with it. However, primary care providers can remedy this situation and truly make a difference in the lives of their patients who may be at risk of acquiring HIV. This eHealth Source™ educational activity comprises 5 chapters, covering an overview of HIV epidemiology, practical approaches to sexual history-taking and assessing patient risk of HIV acquisition, initiation and monitoring of PrEP medication, and overcoming the bias and stigma surrounding HIV and PrEP. Throughout the program, our expert faculty will provide their unique insights surrounding sexual health, HIV prevention, and PrEP, and how these may be incorporated into primary care practice.
- Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27(4):238-243.
- Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841-849.
- Stewart J, Stekler JD. How to incorporate HIV PrEP into your practice. J Fam Pract. 2019;68(5):254-261.
This activity is intended for primary care physicians, nurse practitioners, physician assistants, and other clinicians involved in the care of patients at risk of HIV.
After completing this activity, the participant should be better able to:
- Determine patient risk of HIV infection and eligibility for PrEP by initiating a patient-provider dialogue regarding sexual health and behavior
- Utilize evidence-based HIV-prevention guidelines and safety and efficacy data to initiate and monitor PrEP therapy in eligible patients
- Discuss strategies to reduce stigma related to sexual health, PrEP use, and HIV
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
Physician Continuing Medical Education
PIM designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses is 0.5 APNP credits.
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
Gregory S. Felzien, MD, AAHIVS: Nothing to disclose
Andrea R. Jefferson-Saboor, MSN, FNP-C: Nothing to disclose
Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Instructions to Receive Credit
In order to receive credit, participants must complete the preactivity questionnaire, posttest, and program evaluation. Participants must also score at least a 75% on the posttest.
CPE Questions – PIM Contact Information
Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at email@example.com.